Anti-heart autoantibodies in familial dilated cardiomyopathy.

Department of Cardiological, Division of Cardiology, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.
Autoimmunity (Impact Factor: 2.77). 10/2008; 41(6):462-9. DOI: 10.1080/08916930802031546
Source: PubMed

ABSTRACT Familial aggregation is a feature of myocarditis and dilated cardiomyopathy (DCM). Myocarditis, a clinically polymorphic inflammatory disease of the myocardium, is diagnosed by endomyocardial biopsy (EMB) and may lead to DCM. Mutations in several genes encoding myocyte structural proteins are known monogenic DCM causes, but because of high etiologic and genetic heterogeneity, the gene defects identified so far account for a minority of cases. In the last decade, it has been discovered that autoimmunity plays a pivotal role in myocarditis and DCM that are thought to represent different stages of an organ-specific autoimmune disease in genetically predisposed individuals. None of the available genetic studies in familial DCM has taken into account the autoimmune phenotype markers in the characterization of index patients and relatives, thus it is not known whether or not the described gene defects are involved in the autoimmune form of the disease. In animal models autoimmune myocarditis/DCM can be induced by viral infection, immunization with heart-specific autoantigens, or develop spontaneously in genetically predisposed strains. It may be cell or antibody-mediated; susceptibility is based upon multiple MHC and non-MHC genes. In patients, the diagnosis of autoimmune myocarditis/DCM requires exclusion of viral genome on EMB and detection of serum heart-reactive autoantibodies. They are found in index patients and relatives from about 60% of both familial and non-familial pedigrees and predict DCM development among healthy relatives. Some antibodies have functional effects on cardiac myocytes in vitro, in animal models and possibly in a DCM subset without inflammation, responsive to extracorporeal immunoadsorption. Cardiac-specific autoantibodies, which are shown to be disease-specific for myocarditis/DCM, can be used as biomarkers for identifying patients in whom, in the absence of active infection of the myocardium, immunosuppression and/or immunomodulation may be beneficial and their relatives at risk. Future studies should clarify genetic basis of human autoimmune myocarditis/DCM as well as genotype/immune phenotype correlations.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiomyopathy is one of the major causes of sudden death and/or progressive heart failure. Dilated cardiomyopathy (DCM), comprising 60% of the cases of identified cardiomyopathy, is the most common form of heart muscle disease. Interleukin 17 (IL-17) is a proinflammatory cytokine that has been implicated in the pathogenesis of various diseases. To evaluate the influence of IL-17A and IL-17F gene polymorphisms on the risk of DCM, a case-control study was conducted in a Chinese Han population. The TaqMan® SNP Genotyping Assay was used to genotype the SNP rs2275913 of IL-17A and SNP rs763780 of IL-17F in 288 DCM patients and 421 ethnicity-matched controls. No significant difference in genotypic and allelic frequencies between DCM patients and control subjects was observed. However, Results of stratified analysis revealed that rs763780 was associated with male DCM patients in a dominant genetic model (p = 0.031, OR = 1.83, 95% CI = 1.04 - 3.22). Our results suggest that the tested two IL-17 SNPs, rs2275913 and rs763780, are not found to be associated with DCM in the Chinese population studied.
    Human immunology 01/2013; · 2.55 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Both, innate and cell-mediated immunity contribute to prevention of chronic myocarditis and consecutively, cardiomyopathy. 4us, in resistant C57BL/6 mice myocarditis induced by Coxsackievirus B3 (CVB3)-infection is abrogated by immune-mediated mechanisms. However, susceptible A.BY/SnJ mice develop dilated cardiomyopathy (DCM) due to chronic myocarditis. Cardiac auto-antibodies have been shown to play a pivotal role in the initiation and/or progression of inWammatory DCM. In order to investigate diXerences in the autoimmune response of susceptible and resistant mice to infection with CVB3, the patterns of autoantibodies reacting with heart proteins in A.BY/SnJ and C57BL/6 mice were proYled by 2-D Western blot analysis during the acute and chronic phases of myocarditis up to three months, when the pathophysiological phenotype in the susceptible mice has progressed to DCM. In the early phase of infection both mouse strains displayed similar autoantibody patterns. In contrast, at later time points compared to the resistant C57BL/6 strain susceptible A.BY/SnJ mice displayed a much stronger autoimmune response against proteins associated with cell structure, protein transport as well as primary metabolic processes such as energy production. During chronic myocarditis strong antibody responses against myosin heavy chain 6, mitochondrial and heat shock proteins were observed in A.BY/SnJ mice. Antibodies directed against alpha-enolase, serotransferrin, radixin and two processed myosin protein species accumulated late and only in A.BY/SnJ mice suXering from inWammatory DCM. Functional assignment of the target proteins of cardiac autoantibodies indicates that these might be directly involved in cardiac dysfunction.
    Journal of Integrated OMICS. 12/2012; 2(2):54-63.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Systemic lupus erythematosus is an inflammatory disorder of autoimmune origin that can involve multiple organs. Cardiac compromise can occur in patients with established disease, or it can be the initial manifestation in some of these patients. The heart commitment in this disorder can vary in their severity until producing life-threatening conditions, and it can affect any structure or heart tissue. Additionally, the systemic inflammation present is associated to accelerated atherosclerosis that can evolve to early ischemic heart disease, increasing the risk of cardiovascular illness significantly when it is compared with general population. The main characteristics of heart manifestations in systemic lupus erythematosus are discussed, as well as their diagnosis and treatment.
    Revista Colombiana de Reumatología. 09/2013; 20(3):148-154.